Example of Therapeutic Advances in Urology format
Recent searches

Example of Therapeutic Advances in Urology format Example of Therapeutic Advances in Urology format Example of Therapeutic Advances in Urology format Example of Therapeutic Advances in Urology format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
Look Inside
Example of Therapeutic Advances in Urology format Example of Therapeutic Advances in Urology format Example of Therapeutic Advances in Urology format Example of Therapeutic Advances in Urology format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
open access Open Access

Therapeutic Advances in Urology — Template for authors

Publisher: SAGE
Categories Rank Trend in last 3 yrs
Urology #32 of 94 down down by 20 ranks
journal-quality-icon Journal quality:
Good
calendar-icon Last 4 years overview: 132 Published Papers | 476 Citations
indexed-in-icon Indexed in: Scopus
last-updated-icon Last updated: 19/06/2020
Related journals
Insights
General info
Top papers
Popular templates
Get started guide
Why choose from SciSpace
FAQ

Related Journals

open access Open Access

Hindawi

Quality:  
High
CiteRatio: 4.1
SJR: 1.18
SNIP: 1.896
open access Open Access
recommended Recommended

Wiley

Quality:  
High
CiteRatio: 8.4
SJR: 1.773
SNIP: 1.869
open access Open Access

Springer

Quality:  
Good
CiteRatio: 3.3
SJR: 0.933
SNIP: 1.323
open access Open Access

Elsevier

Quality:  
Good
CiteRatio: 3.0
SJR: 0.861
SNIP: 1.042

Journal Performance & Insights

CiteRatio

SCImago Journal Rank (SJR)

Source Normalized Impact per Paper (SNIP)

A measure of average citations received per peer-reviewed paper published in the journal.

Measures weighted citations received by the journal. Citation weighting depends on the categories and prestige of the citing journal.

Measures actual citations received relative to citations expected for the journal's category.

3.6

12% from 2019

CiteRatio for Therapeutic Advances in Urology from 2016 - 2020
Year Value
2020 3.6
2019 4.1
2018 4.4
2017 5.4
2016 4.3
graph view Graph view
table view Table view

1.115

71% from 2019

SJR for Therapeutic Advances in Urology from 2016 - 2020
Year Value
2020 1.115
2019 0.651
2018 1.011
2017 1.171
2016 0.944
graph view Graph view
table view Table view

1.535

60% from 2019

SNIP for Therapeutic Advances in Urology from 2016 - 2020
Year Value
2020 1.535
2019 0.961
2018 1.025
2017 1.358
2016 1.102
graph view Graph view
table view Table view

insights Insights

  • CiteRatio of this journal has decreased by 12% in last years.
  • This journal’s CiteRatio is in the top 10 percentile category.

insights Insights

  • SJR of this journal has increased by 71% in last years.
  • This journal’s SJR is in the top 10 percentile category.

insights Insights

  • SNIP of this journal has increased by 60% in last years.
  • This journal’s SNIP is in the top 10 percentile category.

Therapeutic Advances in Urology

Guideline source: View

All company, product and service names used in this website are for identification purposes only. All product names, trademarks and registered trademarks are property of their respective owners.

Use of these names, trademarks and brands does not imply endorsement or affiliation. Disclaimer Notice

SAGE

Therapeutic Advances in Urology

Approved by publishing and review experts on SciSpace, this template is built as per for Therapeutic Advances in Urology formatting guidelines as mentioned in SAGE author instructions. The current version was created on 19 Jun 2020 and has been used by 325 authors to write and format their manuscripts to this journal.

Urology

Medicine

i
Last updated on
19 Jun 2020
i
ISSN
1756-2872
i
Impact Factor
High - 1.021
i
Open Access
No
i
Sherpa RoMEO Archiving Policy
Green faq
i
Plagiarism Check
Available via Turnitin
i
Endnote Style
Download Available
i
Bibliography Name
SageV
i
Citation Type
Numbered (Superscripted)
25
i
Bibliography Example
Blonder GE, Tinkham M and Klapwijk TM. Transition from metallic to tunneling regimes in superconducting microconstrictions: Excess current, charge imbalance, and supercurrent conversion. Phys. Rev. B 1982; 25(7): 4515–4532. URL 10.1103/PhysRevB.25.4515.

Top papers written in this journal

open accessOpen access Journal Article DOI: 10.1177/1756287219832172
An introduction to the epidemiology and burden of urinary tract infections.
Martha Medina, Edgardo Castillo-Pino1

Abstract:

Urinary tract infections (UTIs) are the most common outpatient infections, with a lifetime incidence of 50−60% in adult women. This is a narrative review aimed at acting as an introduction to the e... Urinary tract infections (UTIs) are the most common outpatient infections, with a lifetime incidence of 50−60% in adult women. This is a narrative review aimed at acting as an introduction to the e... read more read less

Topics:

Incidence (epidemiology) (54%)54% related to the paper, Epidemiology (50%)50% related to the paper
View PDF
322 Citations
open accessOpen access Journal Article DOI: 10.1177/1756287214526767
Management of iatrogenic ureteral injury
Frank N. Burks1, Richard A. Santucci1

Abstract:

Iatrogenic injury to the ureter is a potentially devastating complication of modern surgery. The ureters are most often injured in gynecologic, colorectal, and vascular pelvic surgery. There is also potential for considerable ureteral injury during endoscopic procedures for ureteric pathology such as tumor or lithiasis. While... Iatrogenic injury to the ureter is a potentially devastating complication of modern surgery. The ureters are most often injured in gynecologic, colorectal, and vascular pelvic surgery. There is also potential for considerable ureteral injury during endoscopic procedures for ureteric pathology such as tumor or lithiasis. While maneuvers such as perioperative stenting have been touted as a means to avoid ureteral injury, these techniques have not been adopted universally, and the available literature does not make a case for their routine use. Distal ureteral injuries are best managed with ureteroneocystostomy with or without a vesico-psoas hitch. Mid-ureteral and proximal ureteral injuries can potentially be managed with ureteroureterostomy. If the distal segment is unsuitable for anastomosis then a number of techniques are available for repair including a Boari tubularized bladder flap, transureteroureterostomy, or renal autotransplantation. In rare cases renal autotransplantation or ureteral substitution with gastrointestinal segments may be warranted to re-establish urinary tract continuity. Laparoscopic and minimally invasive techniques have been employed to remedy iatrogenic ureteral injuries. read more read less

Topics:

Ureteroureterostomy (54%)54% related to the paper, Ureter (53%)53% related to the paper
View PDF
179 Citations
open accessOpen access Journal Article DOI: 10.1177/1756287213513488
The Prostate Health Index: a new test for the detection of prostate cancer.
Stacy Loeb1, William J. Catalona2

Abstract:

A major focus in urologic research is the identification of new biomarkers with improved specificity for clinically-significant prostate cancer. A promising new test based on prostate-specific antigen (PSA) is called the Prostate Health Index (PHI), which has recently been approved in the United States, Europe and Australia. ... A major focus in urologic research is the identification of new biomarkers with improved specificity for clinically-significant prostate cancer. A promising new test based on prostate-specific antigen (PSA) is called the Prostate Health Index (PHI), which has recently been approved in the United States, Europe and Australia. PHI is a mathematical formula that combines total PSA, free PSA and [-2] proPSA. Numerous international studies have consistently shown that PHI outperforms its individual components for the prediction of overall and high-grade prostate cancer on biopsy. PHI also predicts the likelihood of progression during active surveillance, providing another noninvasive modality to potentially select and monitor this patient population. This article reviews the evidence on this new blood test with significant promise for both prostate cancer screening and treatment decision-making. read more read less

Topics:

Prostate cancer screening (66%)66% related to the paper, Prostate cancer (58%)58% related to the paper, Prostate (53%)53% related to the paper
View PDF
163 Citations
open accessOpen access Journal Article DOI: 10.1177/1756287211398255
Role of inflammation in bladder function and interstitial cystitis
Sonal Grover1, Abhishek Kumar Srivastava1, Richard K. Lee1, Ashutosh Tewari1, Alexis E. Te2

Abstract:

Cystitis, or inflammation of the bladder, has a direct effect on bladder function. Interstitial cystitis is a syndrome characterized by urinary bladder pain and irritative symptoms of more than 6 months duration. It commonly occurs in young to middle-aged women with no known cause and in fact represents a diagnosis of exclusi... Cystitis, or inflammation of the bladder, has a direct effect on bladder function. Interstitial cystitis is a syndrome characterized by urinary bladder pain and irritative symptoms of more than 6 months duration. It commonly occurs in young to middle-aged women with no known cause and in fact represents a diagnosis of exclusion. Many factors have been suggested, including chronic or subclinical infection, autoimmunity and genetic susceptibility, which could be responsible for initiating the inflammatory response. However, a central role of inflammation has been confirmed in the pathogenesis of interstitial cystitis. Patients with interstitial cystitis are usually managed with multimodal therapy to break the vicious cycle of chronic inflammation at every step. Patients who develop irreversible pathologies such as fibrosis are managed surgically, which is usually reserved for refractory cases. read more read less

Topics:

Interstitial cystitis (63%)63% related to the paper
View PDF
163 Citations
open accessOpen access Journal Article DOI: 10.1177/1756287211431976
Best practice in the treatment of nonmuscle invasive bladder cancer

Abstract:

Bladder carcinoma is the most common malignancy of the urinary tract. Approximately 75-85% of patients with bladder cancer present with a disease that is confined to the mucosa (stage Ta, carcinoma in situ) or submucosa (stage T1). These categories are grouped as nonmuscle invasive bladder cancer (NMIBC). Although the managem... Bladder carcinoma is the most common malignancy of the urinary tract. Approximately 75-85% of patients with bladder cancer present with a disease that is confined to the mucosa (stage Ta, carcinoma in situ) or submucosa (stage T1). These categories are grouped as nonmuscle invasive bladder cancer (NMIBC). Although the management of NMIBC tumours has significantly improved during the past few years, it remains difficult to predict the heterogeneous outcome of such tumours, especially if high-grade NMIBC is present. Transurethral resection is the initial treatment of choice for NMIBC. However, the high rates of recurrence and significant risk of progression in higher-grade tumours mandate additional therapy with intravesical agents. We discuss the role of various intravesical agents currently in use, including the immunomodulating agent bacillus Calmette-Guerin (BCG) and chemotherapeutic agents. We also discuss the current guidelines and the role of these therapeutic agents in the context of higher-grade Ta and T1 tumours. Beyond the epidemiology, this article focuses on the risk factors, classification and diagnosis, the prediction of recurrence and progression in NMIBC, and the treatments advocated for this invasive disease. read more read less

Topics:

Bladder cancer (58%)58% related to the paper, Carcinoma in situ (51%)51% related to the paper
View PDF
152 Citations
Author Pic

SciSpace is a very innovative solution to the formatting problem and existing providers, such as Mendeley or Word did not really evolve in recent years.

- Andreas Frutiger, Researcher, ETH Zurich, Institute for Biomedical Engineering

Get MS-Word and LaTeX output to any Journal within seconds
1
Choose a template
Select a template from a library of 40,000+ templates
2
Import a MS-Word file or start fresh
It takes only few seconds to import
3
View and edit your final output
SciSpace will automatically format your output to meet journal guidelines
4
Submit directly or Download
Submit to journal directly or Download in PDF, MS Word or LaTeX

(Before submission check for plagiarism via Turnitin)

clock Less than 3 minutes

What to expect from SciSpace?

Speed and accuracy over MS Word

''

With SciSpace, you do not need a word template for Therapeutic Advances in Urology.

It automatically formats your research paper to SAGE formatting guidelines and citation style.

You can download a submission ready research paper in pdf, LaTeX and docx formats.

Time comparison

Time taken to format a paper and Compliance with guidelines

Plagiarism Reports via Turnitin

SciSpace has partnered with Turnitin, the leading provider of Plagiarism Check software.

Using this service, researchers can compare submissions against more than 170 million scholarly articles, a database of 70+ billion current and archived web pages. How Turnitin Integration works?

Turnitin Stats
Publisher Logos

Freedom from formatting guidelines

One editor, 100K journal formats – world's largest collection of journal templates

With such a huge verified library, what you need is already there.

publisher-logos

Easy support from all your favorite tools

Therapeutic Advances in Urology format uses SageV citation style.

Automatically format and order your citations and bibliography in a click.

SciSpace allows imports from all reference managers like Mendeley, Zotero, Endnote, Google Scholar etc.

Frequently asked questions

1. Can I write Therapeutic Advances in Urology in LaTeX?

Absolutely not! Our tool has been designed to help you focus on writing. You can write your entire paper as per the Therapeutic Advances in Urology guidelines and auto format it.

2. Do you follow the Therapeutic Advances in Urology guidelines?

Yes, the template is compliant with the Therapeutic Advances in Urology guidelines. Our experts at SciSpace ensure that. If there are any changes to the journal's guidelines, we'll change our algorithm accordingly.

3. Can I cite my article in multiple styles in Therapeutic Advances in Urology?

Of course! We support all the top citation styles, such as APA style, MLA style, Vancouver style, Harvard style, and Chicago style. For example, when you write your paper and hit autoformat, our system will automatically update your article as per the Therapeutic Advances in Urology citation style.

4. Can I use the Therapeutic Advances in Urology templates for free?

Sign up for our free trial, and you'll be able to use all our features for seven days. You'll see how helpful they are and how inexpensive they are compared to other options, Especially for Therapeutic Advances in Urology.

5. Can I use a manuscript in Therapeutic Advances in Urology that I have written in MS Word?

Yes. You can choose the right template, copy-paste the contents from the word document, and click on auto-format. Once you're done, you'll have a publish-ready paper Therapeutic Advances in Urology that you can download at the end.

6. How long does it usually take you to format my papers in Therapeutic Advances in Urology?

It only takes a matter of seconds to edit your manuscript. Besides that, our intuitive editor saves you from writing and formatting it in Therapeutic Advances in Urology.

7. Where can I find the template for the Therapeutic Advances in Urology?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per Therapeutic Advances in Urology's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

8. Can I reformat my paper to fit the Therapeutic Advances in Urology's guidelines?

Of course! You can do this using our intuitive editor. It's very easy. If you need help, our support team is always ready to assist you.

9. Therapeutic Advances in Urology an online tool or is there a desktop version?

SciSpace's Therapeutic Advances in Urology is currently available as an online tool. We're developing a desktop version, too. You can request (or upvote) any features that you think would be helpful for you and other researchers in the "feature request" section of your account once you've signed up with us.

10. I cannot find my template in your gallery. Can you create it for me like Therapeutic Advances in Urology?

Sure. You can request any template and we'll have it setup within a few days. You can find the request box in Journal Gallery on the right side bar under the heading, "Couldn't find the format you were looking for like Therapeutic Advances in Urology?”

11. What is the output that I would get after using Therapeutic Advances in Urology?

After writing your paper autoformatting in Therapeutic Advances in Urology, you can download it in multiple formats, viz., PDF, Docx, and LaTeX.

12. Is Therapeutic Advances in Urology's impact factor high enough that I should try publishing my article there?

To be honest, the answer is no. The impact factor is one of the many elements that determine the quality of a journal. Few of these factors include review board, rejection rates, frequency of inclusion in indexes, and Eigenfactor. You need to assess all these factors before you make your final call.

13. What is Sherpa RoMEO Archiving Policy for Therapeutic Advances in Urology?

SHERPA/RoMEO Database

We extracted this data from Sherpa Romeo to help researchers understand the access level of this journal in accordance with the Sherpa Romeo Archiving Policy for Therapeutic Advances in Urology. The table below indicates the level of access a journal has as per Sherpa Romeo's archiving policy.

RoMEO Colour Archiving policy
Green Can archive pre-print and post-print or publisher's version/PDF
Blue Can archive post-print (ie final draft post-refereeing) or publisher's version/PDF
Yellow Can archive pre-print (ie pre-refereeing)
White Archiving not formally supported
FYI:
  1. Pre-prints as being the version of the paper before peer review and
  2. Post-prints as being the version of the paper after peer-review, with revisions having been made.

14. What are the most common citation types In Therapeutic Advances in Urology?

The 5 most common citation types in order of usage for Therapeutic Advances in Urology are:.

S. No. Citation Style Type
1. Author Year
2. Numbered
3. Numbered (Superscripted)
4. Author Year (Cited Pages)
5. Footnote

15. How do I submit my article to the Therapeutic Advances in Urology?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per Therapeutic Advances in Urology's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

16. Can I download Therapeutic Advances in Urology in Endnote format?

Yes, SciSpace provides this functionality. After signing up, you would need to import your existing references from Word or Bib file to SciSpace. Then SciSpace would allow you to download your references in Therapeutic Advances in Urology Endnote style according to Elsevier guidelines.

Fast and reliable,
built for complaince.

Instant formatting to 100% publisher guidelines on - SciSpace.

Available only on desktops 🖥

No word template required

Typset automatically formats your research paper to Therapeutic Advances in Urology formatting guidelines and citation style.

Verifed journal formats

One editor, 100K journal formats.
With the largest collection of verified journal formats, what you need is already there.

Trusted by academicians

I spent hours with MS word for reformatting. It was frustrating - plain and simple. With SciSpace, I can draft my manuscripts and once it is finished I can just submit. In case, I have to submit to another journal it is really just a button click instead of an afternoon of reformatting.

Andreas Frutiger
Researcher & Ex MS Word user
Use this template